Evidence map›Paper›PMID 31983177›Full record

Trial reportAsian Pacific journal of cancer prevention : APJCP2020

Efficacy and Safety of Metronomic Chemotherapy Versus Palliative Hydroxyurea in Unfit Acute Myeloid Leukemia Patients: A Multicenter, Open-Label Randomized Controlled Trial.

Saranya Pongudom, Phichayut Phinyo, Yingyong Chinthammitr, Kanyaporn Charoenprasert, Harutaya Kasyanan, Klaijith Wongyai, Jittiporn Purattanamal, Naiyana Panoi, Anoree Surawong

Open access · goldAbstract readComparative StudyMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Asian Pacific journal of cancer prevention : APJCP, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Trial
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Saranya PongudomDivision of Hematology, Department of Internal Medicine, Udon Thani Hospital, Udon Thani, Thailand.ORCID 0000-0003-1441-6739
Phichayut PhinyoCenter for Clinical Epidemiology and Clinical Statistics, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Yingyong ChinthammitrDivision of Hematology, Department of Internal Medicine, Faculty of Medicine Siriraj Hospital, Bangkok, Thailand.
Kanyaporn CharoenprasertDivision of Hematology, Department of Internal Medicine, Si Sa Ket Hospital, Si Sa Ket, Thailand.
Harutaya KasyananDivision of Hematology, Department of Internal Medicine, Buddhachinaraj, Hospital, Phitsanulok,Thailand.
Klaijith WongyaiDivision of Hematology, Department of Internal Medicine, Sawanpracharak Hospital, Nakhon Sawan,Thailand.
Jittiporn PurattanamalDivision of Hematology, Department of Internal Medicine, Maharaj Nakhon Si Thammarat Hospital, Nakhon Si Thammarat,Thailand.
Naiyana PanoiDivision of Hematology, Department of Internal Medicine, Chonburi Hospital, Chon Buri, Thailand.
Anoree SurawongDivision of Hematology, Department of Internal Medicine, Sanprasithiprasong Hospital, Ubon Ratchathani, Thailand.
Chiang Mai University · TH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundManagement of unfit AML patients is a therapeutic challenge. Most hematologists tend to avoid aggressive treatment leaving patients with a choice of best supportive care. We hypothesized that metronomic chemotherapy could be an alternative treatment for unfit AML patients.

methodsA multi-center randomized controlled trial was conducted in seven university-affiliated hospitals in Thailand. Unfit AML patients were recruited and followed up from December 2014 to December 2017. Patients were randomly assigned to receive either metronomic chemotherapy or palliative hydroxyurea. Overall survival rates were compared using Cox's proportional hazard survival analysis.

resultsA total of 81 eligible patients were randomly allocated and included for ITT analysis. The OS rate was higher in group receiving metronomic chemotherapy than in group receiving palliative treatment at 6 and 12 months with borderline significance (6 months HR 0.60; 95%CI 0.36, 1.02; p-value 0.060; 12 months: HR 0.66; 95%CI 0.41, 1.08; p-value 0.097).

conclusionMetronomic chemotherapy could prolong survival time of unfit AML patients, especially in the first 12 months after diagnosis without increasing treatment-associated adverse events.

Indexed as

AgedAntineoplastic Combined Chemotherapy ProtocolsEtoposideFemaleFollow-Up StudiesHumansHydroxyureaLeukemia, Myeloid, AcuteMaleMercaptopurineMiddle AgedPrednisolonePrognosisSurvival RateEtoposideHydroxyureaMercaptopurinePrednisoloneacute myeloid leukemiaElderlyHydroxyureametronomic chemotherapy

Identifiers

PMID31983177
PMCPMC7294042
OpenAlexW3003915272

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.